Remodelin

Remodelin

Catalog Number:
L002370694APE
Mfr. No.:
APE-B4887
Price:
$180
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Remodelin is a potent inhibitor of NAT10 [1].
          N-acetyltransferase 10 (NAT10) is the only identified lysine acetyltransferase that acts on microtubules and histones [1]. NAT10 mainly exists in the nucleolus.
          Remodelin is a potent NAT10 inhibitor. In lamin A/C depletion (siLMNA) cells, remodelin remodeled nuclear architecture through inhibition of NAT10 lysine acetyltransferase activity. In cells derived from LMNA-mutated HGPS patients and primary MRC5 fibroblasts aged in culture, Remodelin significantly decreased the prevalence of misshapen nuclei. In U2OS cells and normal fibroblasts, remodelin inhibited nuclear shape defects induced by farnesyltransferase inhibitors (FTI). In HGPS cells, remodelin reduced the amount of misshapen nuclei, suggesting that inhibition of NAT10 mediated nuclear shape normalization. Also, remodelin reduced DNA damage signaling, reduced SUN1 accumulation at the nuclear envelope, reduced the levels of autophosphorylated ATM and DNA double-strand break markers γH2AX, and improved chromatin and nucleolar organization. In siLMNA and HGPS cells, remodelin inhibited microtubule anchorage to centrosomes [1].

      • Properties
        • Alternative Name
          4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile;hydrobromide
          CAS Number
          1622921-15-6
          Molecular Formula
          C15H15BrN4S
          Molecular Weight
          363.28
          Purity
          98.00%
          Solubility
          ≥36.3 mg/mL in DMSO; insoluble in H2O; ≥2.6 mg/mL in EtOH with ultrasonic
          Storage
          Store at -20°C

          * For Research Use Only

    We Also Recommend

    HPOB

    $206

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.